Clinical Trials Logo

Asthma, Bronchial clinical trials

View clinical trials related to Asthma, Bronchial.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03989635 Withdrawn - Asthma Clinical Trials

Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.

Start date: October 15, 2019
Phase: Phase 2
Study type: Interventional

This is an exploratory, randomized, subject- and investigator-blinded, placebo-controlled mode-of-action study to demonstrate the anti-inflammatory effects of fevipiprant compared to placebo after 12 weeks of treatment in 48 moderate to severe asthma patients with sputum and blood eosinophilia.

NCT ID: NCT00830427 Withdrawn - Clinical trials for Lung Diseases, Obstructive

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects

A7881006
Start date: April 15, 2009
Phase: Phase 2
Study type: Interventional

This study (A7881006) is the first multiple dose study in moderate asthmatic subjects and aims to determine the safety and efficacy of PF-00610355 when subjects take PF-00610355 on a daily basis for 4 weeks in subjects maintained on inhaled corticosteroid.

NCT ID: NCT00540839 Withdrawn - Asthma, Bronchial Clinical Trials

A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)

Start date: November 2007
Phase: Phase 3
Study type: Interventional

A study to determine the effects of montelukast (MK-0476) on pediatric participants with chronic asthma compared with fluticasone. The primary hypotheses are that, over 24 weeks of treatment, montelukast will provide at least the same level of asthma control as inhaled fluticasone as measured by the percentage of days without asthma and that, over 24 weeks of treatment, daily administration of montelukast will be safe and well tolerated in children aged 6 months to 5 years with chronic asthma. This trial was stopped at a time before any participants had actually entered the trial. Based on input from regulatory agencies, it is not necessary to conduct this study; a separate ongoing study was sufficient for regulatory purposes.